The European Commission’s approval allows Jerini to market Firazyr in the EU’s 27 member states, making it the first product to be approved in all EU countries for the treatment of hereditary angioedema.
As announced by Shire on July 3, 2008, Maia Elfte Vermogensverwaltungs, to be renamed ‘Shire Deutschland Investments’, a German indirect subsidiary of Shire Limited, has launched a voluntary public takeover offer for all shares in Jerini.
Subject to completion of certain sale and purchase agreements and registration of the newly issued shares, Shire will have rights to approximately 75% of Jerini’s share capital before the receipt of any takeover offer acceptances.
It is anticipated that the offer will be open for acceptance by the remaining shareholders until the end of the third quarter of 2008 and is contingent upon the fulfillment of certain customary terms and conditions, including approval by relevant merger control authorities.
Sylvie Gregoire, president of Shire Human Genetic Therapies business, said: “We look forward to the completion of our transaction with Jerini which will enable us to work together and ultimately build Firazyr into a global gold standard treatment.”